dc.contributor.author | Lappegård, Knut Tore | |
dc.contributor.author | Kjellmo, Christian Abendstein | |
dc.contributor.author | Hovland, Anders | |
dc.date.accessioned | 2021-12-31T09:39:50Z | |
dc.date.available | 2021-12-31T09:39:50Z | |
dc.date.issued | 2021-07-18 | |
dc.description.abstract | High-density lipoproteins (HDL) are a heterogenous group of plasma molecules with a
large variety in composition. There is a wide specter in lipid content and the number of different
proteins that has been associated with HDL is approaching 100. Given this heterogeneity and the fact
that the total amount of HDL is inversely related to the risk of coronary heart disease (CHD), there
has been increasing interest in the function of specific HDL subgroups and in what way measuring
and quantifying these subgroups could be of clinical importance in determining individual CHD risk.
If certain subgroups appear to be more protective than others, it may also in the future be possible
to pharmacologically increase beneficial and decrease harmful subgroups in order to reduce CHD
risk. In this review we give a short historical perspective, summarize some of the recent clinical
findings regarding HDL subclassifications and discuss why such classification may or may not be of
clinical relevance. | en_US |
dc.identifier.citation | Lappegård, Kjellmo, Hovland. High-density lipoprotein subfractions: Much ado about nothing or clinically important?. Biomedicines. 2021;9(7) | en_US |
dc.identifier.cristinID | FRIDAID 1938432 | |
dc.identifier.doi | 10.3390/biomedicines9070836 | |
dc.identifier.issn | 2227-9059 | |
dc.identifier.uri | https://hdl.handle.net/10037/23562 | |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.relation.journal | Biomedicines | |
dc.rights.accessRights | openAccess | en_US |
dc.rights.holder | Copyright 2021 The Author(s) | en_US |
dc.subject | VDP::Medical disciplines: 700::Clinical medical disciplines: 750 | en_US |
dc.subject | VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750 | en_US |
dc.title | High-density lipoprotein subfractions: Much ado about nothing or clinically important? | en_US |
dc.type.version | publishedVersion | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |